Lightbridge

Phase A — Understand the business

Lens 1 · Company Overview

Lightbridge Corporation (Nasdaq: LTBR; incorporated in Nevada; HQ 11710 Plaza America Drive, Reston, VA) is a single-product, pre-revenue nuclear-fuel technology developer. Its one asset is Lightbridge Fuel™ — a proprietary all-metal (uranium-zirconium) fuel for water-cooled reactors, using multi-lobe fuel rods with a helical-cruciform geometry designed to run cooler and denser than conventional uranium-dioxide (UO₂) ceramic fuel. The pitch is threefold: (1) power uprates — up to ~30% in new-build PWRs, ~17%+ in existing large PWRs; (2) safety — lower operating temperature that (per a DOE-funded Structural Integrity Associates LOCA study) keeps cladding below the ~850–900°C hydrogen-generation threshold implicated at Fukushima; (3) proliferation resistance — roughly half the plutonium in spent fuel.

Business model: there is none yet — the company sells nothing and has never recognized revenue. The intended model "remains under evaluation" (its own words, 16 years after pivoting to metallic fuel) and is variously described as licensing the design to fuel vendors, self-manufacturing at a dedicated facility, or partnering. R&D is executed inside the DOE national-lab complex, principally Idaho National Laboratory (INL) via its operating contractor Battelle Energy Alliance (BEA), under an umbrella SPPA + CRADA.

• Customers: none. Future customers are nuclear utilities and SMR developers; today there are zero binding offtake or LTA host agreements.
• Suppliers / partners: BEA/INL (core R&D), Amentum (engineering services), RATEN ICN Romania (CANDU feasibility), Numerical Advisory Solutions + Studsvik Scandpower (safety-analysis codes), an unnamed specialty-metals maker (cladding alloys), Oklo (co-location MOU, now narrowed — see Lens 8).
• Headcount: 13 full-time employees at 2025-12-31 — a genuine micro-organization outsourcing the science to national labs.
• Contract structure: cost-reimbursable task statements, cancellable on 30–60 days' notice — "not considered firm commitments". No take-or-pay, no recurring revenue, no backlog.

Plain-terms verdict: this is a 13-person, cash-rich research syndicate renting DOE reactors to prove a fuel concept. It is closer to a clinical-stage biotech (a single asset in "trials") than to an operating energy company.

Lens 2 · Supply Chain

Commercial-layer files for the energy topic are absent (kb/energy/wiki/* missing per company-context), so this maps from the filings. Names or it didn't happen:

Upstream (inputs) → Lightbridge → end use:

• Enriched uranium (HALEU, up to 19.75% U-235, in metal form): the critical, non-existent-at-scale input. Today only research quantities exist. Centrus Energy (LEU) is the only licensed Western HALEU producer; DOE supplied the enriched uranium for the current coupon samples. LTBR joined the DOE HALEU Consortium (Jan 2023) to mitigate supply risk.
• Zirconium alloy + cladding: unnamed U.S. specialty-metals manufacturer (MOU + collaboration, Nov 2025) developing cladding alloys.
• Fabrication / co-extrusion: performed at INL today; batch scale requires a dedicated Lightbridge Expandable Fuel Facility (LEFF) that does not exist ("hundreds of millions of dollars" to build at reload scale).
• Irradiation testing: INL's Advanced Test Reactor (ATR) and (planned) the Transient Reactor Test Facility (TREAT); loop-irradiation capacity is gated on new "I-loops" not yet installed.
• Compute: a purpose-bought high-performance computer (~$2.0M in 2025) plus code from NAS and Studsvik for fuel modeling.
• De-conversion / metallization + shipping containers: the industry's UO₂ infrastructure is licensed to 5% oxide; LTBR's metal-at-19.75% needs new conversion, de-conversion, metallization, and shipping-cask licensing that nobody has built.
• Downstream: fuel vendors (Westinghouse / Framatome / GNF) fabricate reload batches; utilities load them; the NRC must license every step.

Chokepoints / single-source dependencies (severe):

1. INL is a single point of failure. ~31% of total R&D flows through the one BEA relationship, and the company "currently primarily relies on INL for developing, testing and evaluating its nuclear fuel". INL has already told them it "may not be able to meet the Company's preferred project timeline" and that "total project cost will exceed the current budget" — a supplier openly signalling slippage.
2. HALEU-metal supply chain does not exist at commercial scale and is on someone else's balance sheet/timeline.
3. ATR loop capacity is "limited and highly competitive" — the physical bottleneck to generating qualification data.

This is a supply chain that is 90% aspirational: almost every named link past the current coupon test is a facility or license that has to be created.

Lens 3 · Competitive Advantages (moats)

The moat is narrow, real-but-unproven IP plus a privileged DOE relationship — not a business moat.

• IP: 11 U.S. patents + 146 foreign patents + 24 pending, on the helical-cruciform metallic U-Zr design, plus trade secrets on fabrication. Caveat that bulls miss: U.S. patents "begin to expire in 2027" — the earliest core protection lapses before the technology is even demonstrated in a commercial reactor. The durable moat, if any, migrates to trade-secret fabrication know-how, which is unproven at full length (12–14 ft rods have never been fabricated with enriched U).
• Switching costs / scale / network effects: none exist — there is no installed base, no customer, no manufacturing.
• Regulatory / relationship moat: the strongest real edge is the umbrella SPPA + CRADA with BEA/INL (extended to 12 years / 2032) and HALEU Consortium membership — access to national-lab reactors and DOE-supplied enriched uranium that a new entrant could not easily replicate.
• Bargaining power: weak on both sides. LTBR needs INL far more than INL needs LTBR (cancellable task orders; INL dictates timeline). It will need utilities and fuel vendors to volunteer their reactors and licensing effort for LTAs — LTBR has no leverage to compel them.
• Product differentiation: genuinely differentiated on paper — management claims Lightbridge Fuel™ is "the only advanced light-water reactor fuel in development that can provide power uprates, cycle-length extensions, improved safety, and load-following in a single product". That claim is untested in a commercial reactor and directly contested by the ATF encroachment (Lens 12/13).

Moat grade: option-value IP, not a defensible franchise. The best defensible asset today is the balance sheet, not the technology.

Lens 4 · Segments

segments.csv is empty because there is nothing to segment. Per the 10-K: one reportable segment — "nuclear fuel technology" — with $0 revenue in both 2025 and 2024. No geographic revenue split (feasibility studies in Romania/CANDU are cost, not revenue). The only meaningful "segmentation" is the cost stack, which is where the story is:

Read: G&A ($14.0M) is larger than all of R&D ($9.2M) — a telling ratio for a company whose entire reason to exist is the science. Of that G&A, $4.4M is stock-based comp. The fastest-growing line is IT (the HPC buy). The trend is accelerating cash consumption, fully expected and fully funded (Lens 11).

---

Phase B — Measure performance

(pre-revenue swap applied: there is no "beat/miss" — the tape is milestones + the loss run-rate + the policy bid)

Lens 5 · Latest print + milestone status (swap for Earnings Result)

Latest financials — Q1 2026 (three months ended 2026-03-31):

• Net loss $6.3M (−$0.20/sh) vs −$4.8M (−$0.24/sh) Q1 2025; G&A $4.3M, R&D $3.3M (+94% YoY), interest income $1.34M.
• Cash $215.7M, total equity $217.6M, 35,000,312 shares out; total liabilities <$1.3M, no debt.
• Weighted-avg shares 32.0M vs 19.5M a year earlier — +64% share-count inflation YoY, the single most important number in the print.

FY2025 (audited, BDO USA): net loss $19.6M; operating cash burn only $14.3M; cash $201.9M (from $40.0M) after raising $176.0M net via the Jefferies ATM (12.6M shares). Accumulated deficit $183.8M.

There is no consensus to beat — analyst coverage is negligible (Lens 7). So the "print" that matters is the milestone tape, and here it is genuinely progressing:

• Nov 2025: first irradiation of enriched U-Zr coupon samples begins in ATR at INL (a real, hard milestone; a management PSA vested on it).
• May 6, 2026: first batch of samples removed from ATR, entering cooldown → post-irradiation examination (PIE) begins late 2026. Testing uses the FAST (Fission-Accelerated Steady-state Test) method with HEU to reach high burnup faster.
• Feb 2025: co-extruded an ~8-ft clad depleted-U-Zr rod — a fabrication milestone (still short of the 12–14 ft enriched rods commercial PWRs need).
• Apr 2026: new SPPA PTS No. 6 (~$4.6M / 36 months) for fabrication-process development.

⚠ Negative delta — the timeline slipped between filings. The FY2025 10-K (Feb 2026) guided commercial-reactor LTA/LTR demonstration "early- to mid-2030s" and purchase orders "late 2030s." The Q1 10-Q (Apr 2026) moved this to demonstration "mid-2030s" and orders "15 years from now" (~2041), deployment ~2 years later (~2043). Two months, a multi-year push-out. Market reaction: irrelevant to fundamentals — the stock trades on policy, not milestones (Lens 8).

Lens 6 · Investor communication & sentiment trend (swap for Earnings Calls)

transcripts/ is empty. As a 13-person pre-revenue micro-cap, LTBR communicates via press releases, business-update webcasts, and filings rather than the quarterly analyst-call/Q&A cadence of an operating company — so a rigorous 3-call sentiment delta isn't available; label the tone read ****:

• Tone is milestone-triumphal and increasingly policy-anchored. The FY2025 10-K and 2026 PRs lean hard on the AI-data-center demand narrative ("~70% U.S. demand growth over 20 years," "300 GW by 2050," "behind-the-meter... data centers") and on federal tailwinds (ADVANCE Act, NRC 12/18-month review mandates, Trump May-2025 executive orders).
• What they've started saying: "FAST/accelerated qualification," "data centers," "co-location," "UPRISE / White House."
• What they've quietly stopped saying: firm commercialization dates (now hedged to "15 years from now"); the Oklo Idaho-Falls co-location (walked back — Lens 8).
• Signal: the communication is competent and honest in the filings (the risk factors and INL-slippage admissions are candid), but the promotional surface (PRs, conference appearances, "best nuclear stock" trade-press) is calibrated to keep the retail/thematic bid alive while the ATM runs. That is the tell of a company whose product is, for now, its own equity.

Lens 7 · Comps (EV-to-cash + thematic; P/E is n/a — pre-revenue)

LTBR at ~$8.70 (late-June 2026), ~35.2M shares → ~$300–305M market cap. Net of ~$214M cash / no debt, enterprise value ≈ $86–90M. Cash/share ≈ $6.0. So the market prices the fuel technology itself at only ~$2.65/share, ~$90M — the rest is T-bills.

Earnings multiples are not applicable (no revenue, GAAP losses). The honest comparison set is thematic nuclear-fuel/SMR names; multiples are ** or n/a**:

Read: among pre-revenue nuclear names LTBR is the smallest and cheapest on absolute EV, and uniquely de-risked on the balance sheet (EV is <½ its cash-adjusted market cap; Oklo/NuScale/NNE carry multi-billion valuations on comparable or later commercialization). The bull framing: "$90M for a DOE-partnered fuel with 30% uprate potential is cheap optionality." The bear framing: it is small and cheap because it is furthest from revenue and least strategically essential — Centrus at $3.4B actually sells the HALEU LTBR will need to buy.

Lens 8 · Stock-Price Catalysts (what actually moves it)

LTBR is a policy-beta / thematic-momentum vehicle, not a fundamentals stock. The >5% moves cluster on macro nuclear-policy news, not company milestones:

• 2025 rally: up ~250% YTD by late May 2025, +~52% in a single week, on Trump's May-2025 nuclear executive orders (DOE directive to boost existing-reactor output, 300 GW-by-2050 target, NRC review-time mandates). May 23, 2025: +20.36% intraday on the EO news.
• Institutional tell: Renaissance Technologies increased its stake +785.8% in Q4 2024 — quant/thematic ownership, not fundamental conviction.
• June 2026: participation in the White House "UPRISE" power-uprate launch (Jun 18) and the ATR sample-removal PR (Jun 25) — the company deliberately syncs its news to the policy calendar.
• Structural overhang: a serial reverse-split history (1:30 in 2009, 1:5 in 2016, 1:12 in 2019) — three reverse splits in a decade is the signature of chronic dilution and a sub-$1 history, and the current open ATM means every rally is met with supply.
• Volatility driver: low float + retail/thematic ownership + no cash-flow anchor ⇒ high beta to the entire "nuclear renaissance" trade (Oklo/NuScale/Centrus move together).

Pattern: the market reacts to DOE/White House/NRC headlines and sector sentiment, and essentially ignores the granular test-program milestones. Own this name for the theme, and it will round-trip with the theme.

---

Phase C — Judge people & books

Lens 9 · Management

• Seth Grae — Founder, CEO, President & Chairman (combined roles). Founded predecessor Thorium Power in 1992 alongside the late Alvin Radkowsky (former head of the U.S. Navy Nuclear Propulsion program under Rickover), renamed Lightbridge in 2009 and pivoted to metallic fuel. Background is law/policy, not nuclear engineering (JD American U., LLM Georgetown); advised the UAE on its civil-nuclear program. ~30+ year tenure.
• Track record — read honestly: three decades, zero revenue, three reverse splits, and a still-"under evaluation" business model. He is a durable fundraiser and policy-navigator who has kept a single-asset science project alive and, in 2025, opportunistically converted a policy rally into a $182M gross raise that fortified the balance sheet. That capital-markets execution is the genuine skill on display. He has not delivered a commercialized product or a paying customer.
• Andrey Mushakov — EVP, Nuclear Operations (co-founder) — the technical operations lead.
• Larry Goldman — CFO — long-tenured (2018 employment agreements for all three).
• Capital allocation: the only allocation decision to date is issue equity → fund R&D at cost → hold the rest in T-bills (interest income $3.6M FY25 / $1.34M Q1'26 now offsets a fifth-to-quarter of the operating loss). No buybacks, no dividends, no debt, no acquisitions. ROE/ROIC are structurally negative (net loss on all-equity capital) and will stay so for a decade+.
• Skin in the game & comp — a red flag on alignment: FY2025 NEO comp is rich for a $0-revenue 13-person company — CEO ~$1.17M cash (salary $596k + bonus $175k + non-equity incentive $401k) plus RSAs/PSAs with grant-date fair value of ~$6.4M (Grae alone). Total SBC was $5.8M in 2025 vs a $19.6M net loss — ~30% of the loss is stock comp. Critically, the tranche PSAs vest partly on "securing a significant amount of fundraising before Dec 31, 2028" — management is explicitly rewarded for raising (dilutive) capital, a direct misalignment with per-share value.
• Archetype: founder-promoter / policy entrepreneur, not an operator. Right profile to keep the option alive and funded through Washington; wrong profile to infer imminent commercialization from.

Lens 10 · Forensic Red Flags

Accounting is clean and simple — the risk here is not fraud, it's dilution and cash-incineration in plain sight:

• Revenue recognition: n/a — no revenue. Removes the classic forensic surface entirely.
• Cash vs earnings: net loss $19.6M vs operating cash burn $14.3M — the gap is non-cash SBC ($5.8M), not aggressive accruals. Cash is real T-bills/bank deposits, audited. No receivables/inventory to inflate (there are none).
• SBC flattering nothing: LTBR reports GAAP losses; SBC is a headline expense, not hidden in non-GAAP adjustments (no non-GAAP metrics pushed). Honest.
• Balance sheet: ~all equity ($203.0M equity on $203.8M assets at YE25; $217.6M/$218.9M at Q1'26). No debt, no leases of note, no goodwill/intangibles capitalized (R&D and even the HPC are expensed as incurred) — conservative. Total liabilities <$1.3M.
• The one estimation-sensitivity flag: milestone-vesting tranche PSAs ($13.3M grant-date fair value) whose expense swings with management's own probability estimates of hitting milestones — a soft, self-assessed input, though modest in dollar terms.
• NOLs: prior ownership changes + no projected taxable income ⇒ full valuation allowance; NOL benefit substantially limited.
• Controls: disclosure controls and ICFR both concluded effective; no material weakness; auditor BDO USA, P.C..

Regulatory findings (required sub-section):

• SEC Litigation Releases / AAERs: none. "No LR found" and "No AAER found" for Lightbridge, 2021-07-10 → 2026-07-10, per SEC EDGAR EFTS.
• Item 3 Legal Proceedings (10-K/10-Q): the company discloses only ordinary-course matters and reports no material pending litigation.
• Non-SEC enforcement (web): search surfaced no FTC/DOJ/FDA/CFPB consent decree, settlement, fine, or penalty against Lightbridge. The regulatory risk that matters is prospective, not historical — NRC licensing, DOE export controls (10 CFR Parts 810/110), and HALEU handling approvals that gate commercialization, not any past wrongdoing.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K/10-Q Item 3 as of 2026-07-10.

---

Phase D — Project & stress-test

(pre-revenue swap: cash-runway-to-catalyst + valuation bridge, not an EPS model — an EPS projection would be fabricated precision for a company ~15 years from revenue)

Lens 11 · Cash-runway-to-catalyst & valuation bridge (swap for Forward Projection)

An EPS-for-three-years model is inapplicable and would be dishonest — LTBR has no revenue line and, by its own Q1'26 guidance, no purchase orders until ~2041. The correct forward question is "does the cash reach the value-inflection catalysts, and what is the option worth?"

Runway:

• Cash ≈ $214M (Q1'26 $215.7M + $1.9M Apr ATM − ~Q2 burn).
• Operating cash burn: FY25 $14.3M; run-rating Q1'26 → ~$18–20M/yr and rising as testing/fabrication scale.
• Interest income (~$5M/yr on the T-bill pile) offsets ~25–30% of the loss.
• Even at a doubled ~$35–40M/yr burn, cash alone funds ~5–6 years — i.e., through PIE (late 2026–2027), loop-irradiation prep, fuel-qualification-plan work, and early LTA design without needing to raise. The near-term thesis is not bankruptcy risk. ****

The real funding cliff is LEFF: batch-reload fabrication capacity is self-described as "hundreds of millions of dollars" — that bill lands in the late-2020s/2030s and cannot be covered by today's cash. Expect either large dilution or a DOE cost-share/strategic-partner dependency that is not yet secured.

Valuation bridge: at ~$8.70, ~$6.0/sh is cash and $2.65/sh ($90M) is the technology option. A crude rNPV framing: peak-sales optionality is enormous if the fuel qualifies (the addressable PWR/BWR/SMR fleet is ~$B's of annual fuel), but probability-of-success is low-single-digit-to-low-double-digit given no commercial demo before the mid-2030s, ATF competition, and supply-chain gaps — and the value is discounted ~15 years. $90M is defensible as cheap optionality and simultaneously hard to argue is mispriced given the discounting. No single point estimate is credible; I decline to fabricate one.

Forecast log (Brier): skipped per --watchlist rules (no genuine committed base case to score; an EPS/forecast.ts line would be manufactured precision).

Lens 12 · Bull vs Bear

Bull case. A cash-fortified ($214M, no debt, ~5–6 yr runway), DOE/INL-partnered developer of the only advanced LWR fuel claiming uprates + longer cycles + safety + load-following in one product, riding a durable, bipartisan nuclear-policy supercycle (300 GW by 2050, AI-data-center baseload demand, NRC review-time mandates). The IP + national-lab access is hard to replicate; the balance sheet removes financing-failure risk that kills most pre-revenue peers; and at a ~$90M EV the technology is priced as a cheap, long-dated call option that a single catalyst — a signed LTA host-utility agreement, a DOE cost-share award, or clean PIE data — could re-rate multiples. Renaissance's stake signals the quant/thematic bid is structural.

Bear case (2–3 permanent-impairment risks).

1. Obsolescence-by-good-enough: ATF vendors (Framatome, GE/GNF, Westinghouse) are pushing to 7–8% enrichment for cycle-extension/uprates. If they deliver "good-enough" uprates in the existing PWR fleet first and cheaper — inside utilities' existing vendor relationships — Lightbridge's core value proposition in the installed base is structurally undercut (management concedes this "could severely weaken or undermine our economic value proposition"). Permanent.
2. The fuel never qualifies / timeline defeats it: full-length (12–14 ft) enriched U-Zr rods have never been fabricated; loop-irradiation needs I-loops not yet installed; INL has pre-warned of slippage and cost overruns; NRC acceptance of accelerated (FAST/HEU) qualification is unproven. A negative PIE result or a multi-year slip pushes commercialization past relevance.
3. Dilution as a way of life: three reverse splits, an always-open ATM, PSAs that pay management to raise capital, and a "hundreds-of-millions" LEFF bill ⇒ today's holders are near-certain to be materially diluted before any revenue. Per-share value can stagnate even if the enterprise succeeds.

Pre-mortem (18 months out, thesis broke): the nuclear-policy trade cooled (an SMR cost blow-up or administration shift), the ATM kept issuing into a falling tape, PIE data came back ambiguous, INL slipped the loop-test schedule another year, and an ATF vendor announced a validated 24-month-cycle uprate — LTBR round-tripped to cash value ($6/sh) with the option premium erased.

Are multiples too high? There are no earnings multiples. On EV-to-cash the name is cheap; on probability-adjusted-value-vs-time it's fair-to-rich. The market is refusing to see (contrarian view) that the balance sheet — not the fuel — is the asset, and that Centrus, which sells the HALEU, is the safer way to own the same policy tailwind.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• What structurally breaks the "business"? There is no business to break — that's the point. 16 years post-pivot, revenue is $0 and orders are self-guided to ~2041. You are underwriting a 2040s outcome with 2026 dollars in a field where the technology roadmap (SMRs, ATF, enrichment) will change many times.
• Concentration: 100% single-asset, single-lab (INL), single-input (HALEU it can't yet buy). Any one crack — INL deprioritization, ATR loop unavailability, a bad PIE — impairs the whole thesis.
• Weaker moat than bulls think: core U.S. patents start expiring in 2027, before commercial demo; the real defensibility is unproven trade-secret fabrication of full-length rods that has never been done.
• Most dangerous competitor bulls underrate: not another metallic-fuel startup — it's incremental ATF from the incumbents, who already own the utility relationships, fabrication, and licensing pathway. "Good enough, from your existing vendor" beats "revolutionary, from a 13-person startup, in the 2030s."
• Worst capital-allocation/incentive move: PSAs that vest on raising money and NEO comp of ~$6M+ grant-date value at a $0-revenue firm — management is paid to dilute you.
• Assumptions that must hold for today's price: continuation of the policy bid and clean PIE and an LTA host agreement and HALEU-metal supply and NRC acceptance of accelerated qualification and LEFF financing without catastrophic dilution. That's a long AND-chain.
• If growth disappoints 20–30%? Meaningless — there is no growth to disappoint. The relevant sensitivity is time-to-milestone and dilution, and both are trending the wrong way (timeline slipped 10-K→10-Q; share count +64% YoY).
• Single scenario that permanently impairs: an incumbent ATF design achieving validated cycle-extension/uprate in the existing fleet in the late 2020s — it removes Lightbridge's near-term market before Lightbridge can reach it.
• But the short is hard: ~$6/sh of cash is a hard floor, the DOE/INL relationship is real, milestones are genuinely advancing, and the policy tailwind can squeeze any short violently. This is a name to be flat or tactically long the theme — not to be structurally short.

Lens 14 · Management Questions (ordered by information value)

1. Do you have any binding commitment from a host utility and an incumbent fuel vendor to accept Lightbridge lead test rods/assemblies in a commercial PWR — and if not, what is the realistic date for the first signed LTA host agreement? (This is the single re-rating gate.)
2. INL has told you it "may not meet the preferred timeline" and that "total project cost will exceed budget" — quantify the slippage (months) and the overrun ($), and your fallback if ATR I-loop capacity doesn't materialize.
3. The Q1 10-Q pushed first purchase orders to "15 years from now" vs the 10-K's "late 2030s" — what changed in two months, and is mid-2030s LTA demonstration still real?
4. LEFF at batch scale is "hundreds of millions" — how is it funded without destroying per-share value, and how much depends on DOE cost-share you have not yet secured?
5. Why do the tranche PSAs vest on "securing significant fundraising by Dec 31, 2028" — how is paying management to dilute shareholders aligned with per-share value?
6. If ATF vendors achieve validated cycle-extension/uprates at 7–8% enrichment first, what is left of Lightbridge's value proposition in the existing large-PWR fleet?
7. Has the NRC given any written indication it will accept accelerated-burnup (FAST/HEU) data in lieu of full-cycle commercial-condition irradiation for qualification?
8. Your core U.S. patents begin expiring in 2027 — how much of the helical-cruciform IP is protected past 2035, and what is the trade-secret strategy to extend the moat?
9. What binding HALEU-metal supply arrangement do you have — are you a customer, partner, or competitor to Centrus, and who builds the de-conversion/metallization/shipping-cask chain, on whose balance sheet?
10. The Oklo Idaho-Falls co-location was dropped on licensing grounds — what did that teach you, and is the fabrication-siting plan now materially delayed?
11. What is the commercial model — license to vendors, self-manufacture, or JV — and when, specifically, do you commit to one after 16 years of "under evaluation"?
12. What single PIE result would most increase your own confidence in the fuel — and what result would make you stop the program?
13. With the ATM open and three prior reverse splits, will you commit to a floor price / NAV threshold below which you will not issue?
14. What is the standalone investment case for Lightbridge if the nuclear-policy tailwind reverses (administration change, SMR cost blow-up, public-perception event)?
15. At 13 full-time employees, is the constraint talent, national-lab access, or capital — and which do you fix first with the $214M?

---